1. Home
  2. ICD-10 PCS Codes
  3. X
  4. W
  5. 0
  6. 4 - Central Vein

Central Vein

  • XW043 - Percutaneous
    • XW0430
      • XW04306 - Introduction Central Vein to New Technology Group 6 with Brexanolone, Percutaneous Approach
      • XW04308 - Introduction Central Vein to New Technology Group 8 with Spesolimab Monoclonal Antibody, Percutaneous Approach
    • XW0432
      • XW04326 - Introduction Central Vein to New Technology Group 6 with Nerinitide, Percutaneous Approach
    • XW0433
      • XW04336 - Introduction Central Vein to New Technology Group 6 with Durvalumab Antineoplastic, Percutaneous Approach
      • XW0433A - Introduction Central Vein to New Technology Group 10 with Bentracimab, Ticagrelor Reversal Agent, Percutaneous Approach
    • XW0434
      • XW0434A - Introduction Central Vein to New Technology Group 10 with Cefepime-taniborbactam Anti-infective, Percutaneous Approach
    • XW0435
      • XW04357 - Introduction Central Vein to New Technology Group 7 with Narsoplimab Monoclonal Antibody, Percutaneous Approach
      • XW04358 - Introduction Central Vein to New Technology Group 8 with Mosunetuzumab Antineoplastic, Percutaneous Approach
      • XW0435A - Introduction Central Vein to New Technology Group 10 with Ceftobiprole Medocaril Anti-infective, Percutaneous Approach
    • XW0436
      • XW04366 - Introduction Central Vein to New Technology Group 6 with Lefamulin Anti-infective, Percutaneous Approach
      • XW04367 - Introduction Central Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach
      • XW04368 - Introduction Central Vein to New Technology Group 8 with Afamitresgene Autoleucel Immunotherapy, Percutaneous Approach
    • XW0437
      • XW04372 - Introduction Central Vein to New Technology Group 2 with Coagulation Factor Xa, Inactivated, Percutaneous Approach
      • XW04377 - Introduction Central Vein to New Technology Group 7 with Trilaciclib, Percutaneous Approach
      • XW04378 - Introduction Central Vein to New Technology Group 8 with Tabelecleucel Immunotherapy, Percutaneous Approach
    • XW0438
      • XW04387 - Introduction Central Vein to New Technology Group 7 with Lurbinectedin, Percutaneous Approach
      • XW04388 - Introduction Central Vein to New Technology Group 8 with Treosulfan, Percutaneous Approach
      • XW0438A - Introduction Central Vein to New Technology Group 10 with Obecabtagene Autoleucel, Percutaneous Approach
    • XW0439
      • XW04396 - Introduction Central Vein to New Technology Group 6 with Ceftolozane/Tazobactam Anti-infective, Percutaneous Approach
      • XW04398 - Introduction Central Vein to New Technology Group 8 with Inebilizumab-cdon, Percutaneous Approach
      • XW0439A - Introduction Central Vein to New Technology Group 10 with Odronextamab Antineoplastic, Percutaneous Approach
    • XW043A
      • XW043A6 - Introduction Central Vein to New Technology Group 6 with Cefiderocol Anti-infective, Percutaneous Approach
      • XW043A7 - Introduction Central Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach
    • XW043B
      • XW043B3 - Introduction Central Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach
      • XW043B6 - Introduction Central Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach
      • XW043B7 - Introduction Central Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach
      • XW043BA - Introduction Central Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach
    • XW043C
      • XW043C6 - Introduction Central Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach
      • XW043C7 - Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach
      • XW043CA - Introduction Central Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach
    • XW043D
      • XW043D6 - Introduction Central Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach
    • XW043E
      • XW043E5 - Introduction Central Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach
      • XW043E6 - Introduction Central Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach
    • XW043F
      • XW043F3 - Introduction Central Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach
      • XW043F5 - Introduction Central Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
      • XW043F6 - Introduction Central Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach
      • XW043FA - Introduction Central Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach
    • XW043G
      • XW043G5 - Introduction Central Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach
      • XW043G6 - Introduction Central Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
      • XW043G7 - Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach
    • XW043H
      • XW043H5 - Introduction Central Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach
      • XW043H6 - Introduction Central Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
      • XW043H7 - Introduction Central Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach
    • XW043J
      • XW043J7 - Introduction Central Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach
    • XW043K
      • XW043K7 - Introduction Central Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach
      • XW043K9 - Introduction Central Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach
    • XW043L
      • XW043L6 - Introduction Central Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach
      • XW043L7 - Introduction Central Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach
    • XW043M
      • XW043M7 - Introduction Central Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach
    • XW043N
      • XW043N7 - Introduction Central Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach
    • XW043P
      • XW043P9 - Introduction Central Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach
    • XW043Q
      • XW043Q5 - Introduction Central Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach
      • XW043Q9 - Introduction Central Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach
    • XW043R
      • XW043R9 - Introduction Central Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach
    • XW043S
      • XW043S5 - Introduction Central Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach
    • XW043W
      • XW043W5 - Introduction Central Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach